SUMMARY S-100 protein was determined by Particle Counting ImmunoAssay in the CSF of patients with various neurological disorders. With a limit of sensitivity of 2 5 ,ug/l this brain-specific protein was detected only in samples from patients with acute damage of the central nervous system, particularly in compression of the spinal cord by tumour, ischaemic disorders, subarachnoid bleeding and haematoma, and viral or suspected viral infections. Our results support the assumption that S-100 is a reliable index of central nervous system damage and that changes in its concentration could have a prognostic value.
S-100 protein is an acidic protein of molecular weight 21,000' found essentially in the nervous system of vertebrates. This protein is called "S-100" because of its solubility in 100% saturated ammonium sulphate at neutral pH. A characteristic of S-100 is its structural changes caused by calcium ions.3 S-100 is, in fact, a family of proteins4`8 shown by complement fixation and cross-immunoelectrophoresis9 to be antigenically different. Two main types have been described.67 S-100a containing two different subunits (a and fi subunits) and S100b, two identical subunits (3 subunits).
S-100, the function of which is still unknown, is located mainly in the astrocytes'0-'9 but has also been detected in the interstitial cells of the pineal gland, '6 in satellite cells of the adrenal medulla and the superior cervical ganglion,20 in the pituicytes and the stellate cells of the pituitary gland,2' 22 in melanocytes,23 in cells with morphological features of Langerhans cells in the skin,23 in malignant melanomas,21 and in acoustic neurinomas, some- times in large amounts. 26 hypothesis that S-100 is released into the cerebrospinal fluid (CSF) by lesions of the central nervous system (CNS) and that its determination can be useful in assessing the extent of braini damage.
Materials and methods
Patients The CSF was collected for routine analysis from patients of the Department of Neurology, Cliniques SaintLuc, Brussels by spinal puncture. After centrifugation 0( 5 to 2 ml aliquots were kept frozen at -20°C. The clinical records of these patients were reviewed retrospectively. Patients with unconfirmed diagnoses were excluded from the study. The control group comprised non-neurological patients suffering from minor neurosis but devoid of clinical signs of neurological disorders. Electroencephalography and computed tomography were normal, as well as CSF analyses comprising total protein content (below or equal to 0 4 g/l), cell count (below or equal to 5/cmm) and agar gel electrophoresis.
Purification of S-100 S-100 was isolated from bovine brains obtained at the abbatoir immediately after death of the animal and purified as described by Steward. Ca + + to samples, gel and buffers slowed down the mobility of S-100 in disc-gel electrophoresis (fig 1) because of the structural changes 3 of the protein.
Anti-S-100 antiserum Four rabbits were injected twice a month with a methylated bovine serum albumin S-100 conjugate.27 Bovine serum albumin (bSA) was from Calbiochem, la Jolla, California. After three injections, blood (50 ml) was collected one week after each injection. activated latex was added 300 ,ug F(ah'). Such a preparation which was sufficient for 300 assays was stored at -20°C in small aliquots. The assays were calibrated with purified S-100, serially diluted in 0 1 M glycine buffer, pH 9-2, containing 9 g/l of NaCI (GBS), 10 g/l bSA and made 5 mM in CaCl2. Into the reaction tube were injected sequentially and automatically 30 p.1 each of the sample, of the GBS containing 5 mM CaCl2, 60 g/l polyethylene glycol and 10 ml/l Tween 20, and of the F(ab' )2-coated particles 200 times diluted in GBS containing 2-5 ml/l Ficoll (Pharmacia). Incubation time was 35 minutes.
Results and Discussion THE S-100 IMMUNOASSAY A plot of peak heights or concentration of free particles vs log of S-100 concentration formed a decreasing sigmoid curve from 2-5 to 250 ,ug/l (fig 2) . For greater accuracy samples containing more than 50 ,ug/l were serially diluted. The most important factor which affected the immunoassay was the presence or absence of Ca+ + (fig 3) and 10 g/l bSA or the same medium containing 50 ,ug/l of S-100. Analytical recovery was 95% with a coefficient of variation (CV) of 13%.
PRECISION
The intra-assay precision was studied in three CSF samples containing 7-7, 11 and 19 ,ug/l of S-100, the assays being repeated 10 times on the same day. The CV were respectively 12-7, 4-7 and 4-4%. The inter-assay precision was studied on samples at three concentrations of S-100, 4 5, 9-9 and 24 ,ug/l, the assays being repeated once each day for 8 days. The CV were respectively 16-9, 7 and 6-7%. and haematoma, and viral or suspected viral infections (fig 4) . All these disorders have in common acute damage of the CNS.
Samples with high concentration of S-100 were retested at three or four dilutions. All of the results were distributed in parallel to the calibration curve. Therefore one may assume that the immunoreactive material was actually S-100 and that fragments or aggregates of S-100 presumably did not interfere in the assay.
The patients of the stroke group were not representative of this type of disease because lumbar puncture is usually reserved for those with difficult diagnosis such as thrombosis of basilar and spinal arteries, which irrigate a relatively small region of the brain. In this case, less S-100 should be released than in case of large hemispheric infarction. One has also to take into account that the CSF is often collected a few days after the stroke with the possibility, that S-100 released by the necrotic tissue has been eliminated. Interestingly, in viral or suspected viral infections of the CNS, S-100 was found not only in patients with herpetic encephalitis and transverse myelitis, both of which extensively injure the CNS, but also in some patients with benign lymphocytic meningitis (5 cases out of 17). This suggests that the infectious process affected not only the meninges but also the nervous tissue. It should be noted that significant amounts of S-100 were found in the CSF of four patients out of 10 with Guillain-Barre polyradiculoneuritis, whereas only three patients out of 28 with other peripheral neuropathies were positive. High levels of S-100 in 36 who found by complement fixation S-100 concentrations above 6 ,ug/l in the CSF of 70% of their patients with acute relapse of multiple sclerosis. This finding is rather surprising as recent immunohistochemical studies failed to detect S-100 in oligodendrocytes" 13 which are selectively destroyed with the myelin sheath by multiple sclerosis. Whereas our 90 patients had low levels of S-100 one patient out of six with optic neuritis had a high level of S-100. One may therefore wonder whether this particular case was related or not to multiple sclerosis.
PROGNOSTIC VALUE OF S-1)0 LEVELS
In three patients with herpetic encephalitis we observed that the prognosis of the disease was related to the level of S-100 in the first sample of CSF taken during the acute phase of the disease (table). In our study of transverse myelitis, also restricted to three patients, the poor prognosis was associated more with increased or persistent high levels of S-100 than to the absolute value in the first sample. It should be noted that in a patient who recovered from stroke the S-100 level dropped from 70 ,ug/l to 18 ,ug/l in only two days.
In conclusion, our results support the assumption that S-100 in the CSF is a reliable index of CNS injury3536 and our study of a few patients suggest that the S-100 level and its changes could have a prognostic value. 
